Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis.
Authors:
- Daniella D'IppolitoDDDaniella D'Ippolito
- Michele PisanoMPMichele Pisano
- 1 September 2018
- journal article
- Vol. 43 (9) , 532-535
Abstract
Dupilumab (Dupixent) for atopic dermatitis.Keywords
This publication has 10 references indexed in Scilit:
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Atopic dermatitisThe Lancet, 2016
- Influences of Environmental Chemicals on Atopic DermatitisToxicological Research, 2015
- Atopic Dermatitis: Global Epidemiology and Risk FactorsAnnals of Nutrition and Metabolism, 2015
- Systemic Side-Effects of Topical CorticosteroidsIndian Journal of Dermatology, 2014
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitisGenome Research, 2012
- Filaggrin Mutations Associated with Skin and Allergic DiseasesNew England Journal of Medicine, 2011
- Treatment options for atopic dermatitis.2007